Credit Suisse Group Boosts Smith & Nephew (SN) Price Target to GBX 1,390

Smith & Nephew (LON:SN) had its target price upped by Credit Suisse Group from GBX 1,330 ($17.38) to GBX 1,390 ($18.16) in a research report sent to investors on Friday morning. The brokerage currently has a neutral rating on the stock.

A number of other brokerages have also issued reports on SN. HSBC lowered Smith & Nephew to a hold rating and boosted their price target for the company from GBX 1,400 ($18.29) to GBX 1,500 ($19.60) in a report on Tuesday, October 16th. UBS Group reiterated a neutral rating on shares of Smith & Nephew in a report on Friday, October 26th. JPMorgan Chase & Co. reiterated a neutral rating and issued a GBX 1,477 ($19.30) price target on shares of Smith & Nephew in a report on Tuesday, January 8th. Berenberg Bank boosted their price target on Smith & Nephew from GBX 1,370 ($17.90) to GBX 1,475 ($19.27) and gave the company a hold rating in a report on Friday, November 2nd. Finally, Morgan Stanley upgraded Smith & Nephew to an overweight rating and boosted their price target for the company from GBX 1,457 ($19.04) to GBX 1,692 ($22.11) in a report on Monday, December 10th. Nine research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Smith & Nephew has an average rating of Hold and an average target price of GBX 1,479.36 ($19.33).

SN opened at GBX 1,469.50 ($19.20) on Friday. Smith & Nephew has a one year low of GBX 1,173 ($15.33) and a one year high of GBX 1,442 ($18.84).

The company also recently declared a dividend, which will be paid on Wednesday, May 8th. Investors of record on Thursday, April 4th will be issued a $0.22 dividend. This is a positive change from Smith & Nephew’s previous dividend of $0.14. The ex-dividend date of this dividend is Thursday, April 4th. This represents a dividend yield of 1.1%.

About Smith & Nephew

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

Recommended Story: Bull Market

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with's FREE daily email newsletter.

Leave a Reply